X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PMN400 is a lead vaccine candidate, targeting toxic alpha-synuclein protein clumps in cells. It is being evaluated in preclinical studies for the treatment of multiple system atrophy, parkinson’s disease and dementia with lewy bodies.
Lead Product(s): PMN400
Therapeutic Area: Neurology Product Name: PMN400
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
PMN310 is a novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ). It is under phase 1 clinical development for the treatment of Alzheimer's disease.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The proceeds will be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease (AD).
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: BTIG, LLC
Deal Size: $20.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 08, 2023
Details:
The net proceeds are expected to be used to advance the clinical development of ProMIS’ lead therapeutic candidate, PMN310, a monoclonal therapeutic antibody designed for the treatment of Alzheimer's disease by selectively targeting the toxic oligomers of amyloid-beta.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Affinity Asset Advisors
Deal Size: $20.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 21, 2023
Details:
PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
PMN310 is a novel monoclonal antibody which is designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) that are believed to be a major driver of alzheimer’s disease.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
The proceeds from the offering will be used to advance ProMIS’ lead product candidate, PMN310, into a first-in-human study which the Company plans to commence in 2023, subject to FDA’s acceptance of an Investigational New Drug Application (IND).
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fenway Sports Group
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 12, 2022
Details:
PMN310, is a monoclonal antibody for Alzheimer’s disease created with a novel, proprietary method for generating and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
PMN310 is an antibody that binds to the neurotoxic amyloid beta aggregates, preventing additional amyloid beta monomers from adding to them. Therefore, PMN310 may potentially neutralize toxic aggregates and prevent neurodegeneration.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
PMN310, is a monoclonal therapeutic antibody designed for treatment of Alzheimer’s disease. By selectively targeting toxic oligomers of amyloid-beta, showed a significant cognitive benefit in a widely recognized animal model of AD.
Lead Product(s): PMN310
Therapeutic Area: Neurology Product Name: PMN310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
